Cyclosporine Use in Dermatology

Introduction to Cyclosporine

The British Journal of Dermatology recommends cyclosporine as an effective immunosuppressive agent for severe dermatological conditions, but requires careful monitoring for nephrotoxicity and hypertension, with short-term intermittent courses (up to 6 months) being the safest approach to minimize long-term risks 1, 2

Cyclosporine is licensed for psoriasis and atopic dermatitis in patients ≥16 years old, but widely used for various inflammatory and autoimmune skin conditions 2
The British Journal of Dermatology suggests that cyclosporine is highly effective for severe psoriasis vulgaris, erythrodermic psoriasis, generalized pustular psoriasis, and psoriatic nail dystrophy 2, 3
The British Journal of Dermatology recommends cyclosporine for severe atopic dermatitis refractory to conventional treatments 4

The standard dosing range for cyclosporine is 2.5-5 mg/kg/day orally, divided into two doses, as recommended by the British Journal of Dermatology 1, 2
The initial dose for severe disease is 5 mg/kg/day for rapid control, according to the British Journal of Dermatology 2
For less urgent cases, the British Journal of Dermatology suggests starting with a lower dose (2.5-3 mg/kg/day) and increasing if needed 1, 2

The British Journal of Dermatology recommends that before treatment, a complete physical examination, blood pressure measurements, baseline serum creatinine, BUN, CBC, serum magnesium, potassium, uric acid, lipids, hepatitis screening, and pregnancy test should be performed 1, 5, 6
The British Journal of Dermatology suggests monitoring serum creatinine and blood pressure every 2 weeks for the first 2 months 1, 7

The Journal of the American Academy of Dermatology recommends using calcium channel blockers (especially isradipine) to manage cyclosporine-induced hypertension 7, 6
The British Journal of Dermatology suggests avoiding thiazide diuretics and potassium-sparing diuretics 7

The British Journal of Dermatology warns that cyclosporine is metabolized by cytochrome P450 (especially CYP3A4), leading to numerous drug interactions 2, 8
The BMJ recommends avoiding certain drugs, such as aminoglycosides, amphotericin, trimethoprim, ketoconazole, phenytoin, rifampicin, isoniazid, and NSAIDs, when taking cyclosporine 9, 10

The British Journal of Dermatology suggests that cyclosporine is not teratogenic based on transplant experience, but should be avoided during pregnancy unless benefits outweigh risks 4
The British Journal of Dermatology recommends avoiding breastfeeding while taking cyclosporine, though limited reports show no adverse outcomes 4

The British Journal of Dermatology recommends using intermittent short courses rather than continuous therapy to minimize risks 1, 2
The Journal of the American Academy of Dermatology suggests combining cyclosporine with topical treatments to reduce the required dose 1
The British Journal of Dermatology recommends providing written information to patients about potential side effects and drug interactions 5

The British Journal of Dermatology notes that cyclosporine is less expensive than biological agents but more costly than methotrexate 5
The British Journal of Dermatology estimates the annual cost for psoriasis treatment at 5 mg/kg/day to be approximately $10,000 (US study) 5

For pustular psoriasis, the American Academy of Dermatology recommends tapering cyclosporin by reducing the dose by 1 mg/kg/day weekly after achieving disease control, rather than stopping abruptly, as this approach delays relapse by approximately 4 days while maintaining safety 11, 12, 13
Start cyclosporin at 5 mg/kg/day divided into two doses for rapid control of pustular psoriasis, as this severe variant requires aggressive initial management 14
Continue treatment for 12-16 weeks or until achieving ≥90% clearance of pustular lesions, as recommended by the American Academy of Dermatology 15, 11, 13

Once disease control is achieved, reduce cyclosporin by 1 mg/kg/day each week until complete cessation, as this stepwise approach is superior to abrupt discontinuation based on evidence from 365 patients with severe psoriasis 11, 12, 13
The median time to relapse with gradual taper is 113 days, compared to 109 days with abrupt cessation, with a statistically significant difference (P = 0.038) 11, 12, 13
At a maintenance dose of 3.0 mg/kg/day, 58% of patients maintained improvement through 24 weeks, according to the American Academy of Dermatology 12, 13

Monitor serum creatinine and blood pressure every 2 weeks during tapering, as recommended by the British Journal of Dermatology 14
Initiate alternative therapy before completing cyclosporin taper to maintain disease control, as recommended by the American Academy of Dermatology 11
The combination of tapering plus topical therapy shows lower relapse incidence than abrupt cessation with topical therapy, although specific data is not provided 11, 12, 13

Never stop cyclosporin abruptly in pustular psoriasis, as this can precipitate rebound with erythrodermic or generalized pustular flares, according to the BMJ 16
Avoid simultaneous use of NB-UVB phototherapy with cyclosporin due to photocarcinogenesis risk, as recommended by the American Academy of Dermatology 11, 12
Approximately 30% of patients remain relapse-free 6 months after cyclosporin cessation with proper tapering, although specific data is not provided 11, 12, 13
Median time to relapse is approximately 3-4 months after stopping therapy, according to the American Academy of Dermatology 11, 12, 13
Short intermittent courses (2-12 weeks) are well tolerated with only 8% discontinuing due to adverse effects, as reported by the American Academy of Dermatology 11, 12, 13

Cyclosporine is only available as oral formulations for dermatologic use, and topical cyclosporine formulations have proven ineffective, according to the British Journal of Dermatology 17, 18

The molecular properties of cyclosporine, a neutral, hydrophobic, cyclic polypeptide with a molecular weight of 1203 Da, make topical delivery problematic and limit skin penetration 17

Cyclosporine is available in oral formulations, including the original formulation, which is an olive oil-based solution with lower and more variable bioavailability, now largely superseded by the microemulsion formulation 17

The drug is reserved for severe disease as a second-line agent due to its narrow therapeutic index and risks of nephrotoxicity and hypertension, as recommended by the British Journal of Dermatology 17, 18